Literature DB >> 11720642

Direct costs of health care for HIV/AIDS patients in Belgium.

R C Decock1, A M Depoorter, D De Graeve, R Colebunders.   

Abstract

The cost of HIV/AIDS care was measured in Belgium in 1996. This paper is concerned with direct costs (formal and informal care). This is a prospective study, stratified by CDC-disease stage. A societal point of view was chosen. Eighty-two sequential patients agreed to join the study during outpatient visits. Data on service use and costs were obtained through a care-cost diary kept over three months. Half of the patients (41) returned a completed diary, which reduced the sample size considerably. Additional billing data were obtained from different sources and by calculating the time spent for certain services. In stage A (asymptomatic HIV), the mean (+/- SD) annual total direct costs are US$2,373 (2,079), rising to US$8,401 (7,520) in stage B (symptomatic HIV) and ending up at US$27,373 (22,087) in stage C (full blown AIDS). A difference in balance of costs at different stages of disease was observed. The principal cost of outpatient pharmaca in HIV patients is overtaken by the cost of hospitalization in AIDS patients. The cost of informal care is considerable (40% of the total cost) from stage B onwards. Health care use and costs increase with severity of illness.

Entities:  

Mesh:

Year:  2001        PMID: 11720642     DOI: 10.1080/09540120120076887

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  5 in total

1.  [Economic aspects of ambulatory and inpatient treatment of HIV positive patients].

Authors:  M Stoll; R E Schmidt
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

2.  Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Authors:  Karen Moeremans; Lieven Annemans; Mickael Löthgren; Gabriele Allegri; Veronique Wyffels; Lindsay Hemmet; Karin Caekelbergh; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  [Cost and factors associated with the prescription of non-antiretroviral drugs among HIV-infected patients under antiretroviral therapy in a reference hospital in Morocco].

Authors:  Hicham Titou; Mohammed Boui; Naoufal Hjira
Journal:  Med Trop Sante Int       Date:  2022-01-21

5.  The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.

Authors:  Hartmut B Krentz; M Christopher Auld; M John Gill
Journal:  CMAJ       Date:  2003-07-22       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.